The Interdependence 2012 program features the latest findings from peer-reviewed researchers and clinicians in a comprehensive range of SCI-related subjects. Research teams and organizations from Denmark, Switzerland, Australia, China, UK, Belgium, USA and Canada will share their work and present the newest treatments and technologies in the field.The conference is produced by the Rick Hansen Foundation, a registered charitable organization that provides leadership to create more accessible and inclusive communities and find a cure for spinal cord injury (SCI). For more information, visit www.rickhansen.com/What-We- Do/Interdependence-2012.aspx.

PRINT PDF

InVivo has pioneered a new treatment that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after a traumatic spinal cord injury. Today there is no effective treatment for the spinal cord for paralysis caused by SCIs, and the market potential is estimated to be over $10 billion.

“We are off to a strong start for 2012 and the first quarter was marked by significant achievements and milestones for InVivo”, said Frank Reynolds, InVivo’s Chief Executive Officer. We are creating a new paradigm for the treatment of neurological injuries and are at an inflection point in our growth. By the end of 2012, we expect to have several product applications under review by the FDA. Our biopolymer scaffolding device for the treatment of acute SCIs is poised to enter human clinical trials during the second half of 2012. We expect to submit hydrogel-based applications to the FDA for the treatments of SCI and chronic pain from peripheral nerve injuries later this year. During the first quarter of 2012, we strengthened our balance sheet by closing an oversubscribed $20mm+ public offering led by globally recognized health care investment institutions. In addition, we added key leadership to our management team to drive product development and commercialization.”

Recent Corporate Highlights

Biopolymer Scaffolding Scheduled to Enter Clinical Studies for SCI in 2012: InVivo expects to commence a pilot human clinical trial during the second half of 2012, pending approval of an Investigational Device Exemption (IDE) application by the FDA. Following a meeting with the FDA held in April, the Company is expecting the product to be regulated under the Humanitarian Use Device/Humanitarian Device Exemption (HUD/HDE) pathway that should accelerate commercialization. The pilot study will be an open label study and is designed to evaluate the safety and efficacy in SCI patients following treatment with the biopolymer scaffolding. This study follows promising pre-clinical studies completed in non-human primates. InVivo is the first to successfully demonstrate functional improvement in non-human primates that were paralyzed after a spinal cord injury model.

Submissions to be Filed with the FDA for Injectable Hydrogel to Treat Peripheral Nerve Injuries and SCI: InVivo is conducting a preclinical study with Geisinger Health System to evaluate the Company’s injectable biocompatible hydrogel for the treatment of pain caused by peripheral nerve compression. Approximately 3.2 million pain injections are performed annually to treat back, neck and leg pain caused by peripheral nerve injuries. InVivo’s hydrogel is designed to time-release anti-inflammatory drugs for extended pain relief. The product addresses an estimated $15 billion market for peripheral nerve injuries. InVivo expects to file FDA applications during 2012 for the use of the injectable hydrogel to treat peripheral nerve injuries and SCI.

Raised $20mm+ of Equity Capital: In February 2012, InVivo completed a $20mm+ public offering led by a select group of institutional investors. Net proceeds to InVivo were approximately $18.1mm. InVivo also has the potential to receive an additional $18.6mm of capital from the exercise of previously issued outstanding warrants.

Key Additions to the Management Team: InVivo recently announced the appointments of Jack Harvey, formerly of Pervasis, as Senior Director of Manufacturing, Brian Hess, formerly of Stryker, as Director of Product Development, and Celina Chang, formerly of Pervasis, as Senior Scientist. Under the leadership of new Chief Science Officer, Edward Wirth, MD, PhD, InVivo has established a foundation for the further advancement of chronic spinal cord injury technologies.

New Global Headquarters: InVivo has signed a multi-year lease for a 21,000 square foot facility at One Kendall Square in Cambridge, Massachusetts. The new state-of-the-art facility will bring all of the Company’s operations under one roof and will house corporate offices, a vivarium, laboratory space and a cGMP clean room for manufacturing.

Financial Results

For the three months ended March 31, 2012, the Company reported net income of $3,150,000 or $.05 per diluted share, compared to a net loss of $1,278,000, or $.02 per diluted share, for the three months ended March 31, 2011. Included in results for the three months ended March 31, 2012 and 2011 were non-cash derivative gains of $5,613,000, and $121,000, respectively, reflecting decreases in the fair value of the derivative warrant liability. Exclusive of the non-cash derivative gain, the pro forma net loss for the three months ended March 31, 2012 was $2,463,000, or $.04 per diluted share, compared to a pro forma net loss of $1,399,000, or $.03 per diluted share for 2011.

Total operating expenses for the three months ended March 31, 2012 were $2,461,000 compared with $1,401,000 for the three months ended March 31, 2011. The Company’s cash balance increased to $19.6mm at March 31, 2012 from $4.4mm at December 31, 2011. In February 2012, InVivo completed a $20mm+ public offering and issued 9,523,810 shares of common stock at a price to the public at $2.10 per share. Net proceeds to InVivo were approximately $18.1mm.

(Tables to follow)

PRINT PDF

CAMBRIDGE, Mass. (May 11, 2012) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), announced today the appointment of Jack Harvey as Senior Director of Manufacturing and Celina Chang as Senior Scientist as the Company ramps up preparations for a human clinical trial and begins to expand its product portfolio to other nervous system conditions.

Mr. Harvey will lead InVivo Therapeutics’ production of GMP polymer-based biomaterial technologies. Leveraging his seven years as the Director of Manufacturing at Pervasis Therapeutics, Inc., where he led combination biomaterial and cell therapy products through the FDA, Mr. Harvey will lend his knowledge to InVivo’s existing and future product pipeline. He will manage contracted and internal resources as well as Chemistry, Manufacturing and Control (CMC) development and manufacturing scale up. Mr. Harvey received his B.A. in biology from Harvard University and his M.P.H. Health Law from Boston University, School of Public Health.

“I’m excited to lead InVivo’s optimization of GMP biomaterial technology manufacturing processes,” Mr. Harvey said. “Spinal cord injury treatments are a very promising field, and I’m eager to provide patients with viable solutions for SCI and other nervous system disorders.”

Ms. Chang also previously worked at Pervasis as a scientist charged with process improvement for the company’s three-dimensional polymer matrix embedded with cells. At InVivo Therapeutics, Ms. Chang will lead the execution and review of experiments per GMP and GLP regulations, and undertake the analysis of various cultured cells for InVivo’s chronic spinal cord injury therapies. Prior to Pervasis, Ms. Chang worked at Ortec International, focused on advancing regenerative medicine and stem cell therapies. She holds a B.S. in biological engineering from Cornell University.

“We strongly believe that combination therapies are the future of chronic spinal cord injury, and I look forward to developing these technologies,” said Ms. Chang.

Said InVivo Chief Executive Officer Frank Reynolds, “InVivo is at an inflection point in our growth, and adding industry leaders like Jack and Celina will take our platform technology in new directions. We are creating a new paradigm in the treatment of neurological injuries, and as our team evolves we are pleased that we continue to attract the best in our business, enabling us to expedite our products to market.”

For more information about InVivo Therapeutics’ technologies, visit www.invivotherapeutics.com.

PRINT PDF

CAMBRIDGE, Mass. (May 8, 2012) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that CEO Frank Reynolds is scheduled to appear on KGO-TV in San Francisco on Wednesday, May 9th during their 6:00am PDT newscast.

InVivo Therapeutics has pioneered a new treatment that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after a traumatic spinal cord injury. In addition to the scaffold, Reynolds will discuss applications for the technology in other areas of the nervous system, including additional products the company intends to submit to the U.S. Food and Drug Administration (FDA) this year.

“Our technology is a true platform that can be leveraged to create many products, including treatments for peripheral nerve injury and other conditions. We’re currently under review at FDA for our first spinal cord injury treatment, and we look forward to receiving approval to begin those human studies in 2012,” said Reynolds.

KGO-TV is the ABC affiliate for the San Francisco market and airs locally on channel 7.

PRINT PDF

 

CEO Frank Reynolds discusses InVivo Therapeutics on KGO-TV in San Francisco.

Following the meeting, the Company is expecting the biopolymer scaffolding device to be regulated under the Humanitarian Use Device/Humanitarian Device Exemption (HUD/HDE) pathway. Before human clinical studies can commence, the FDA must approve the Company’s IDE filing, for which the FDA has agreed to an open dialogue as part of the final process toward gaining approval. During the FDA meeting, the Company addressed several points in the FDA’s feedback including the proposed design and clinical protocol for the study.

“This is a significant step for all patients waiting for first in-man data using biomaterials for spinal cord injuries,” said Frank Reynolds, InVivo’s Chief Executive Officer. “We are pleased that our core team of multidisciplinary scientists, led by my partner, Bob Langer, has had the opportunity to meet with the FDA to discuss our platform technology. We are encouraged by the communication we have had with the FDA to this point, and pending approval of the IDE, we expect the clinical trial for our treatment of acute spinal cord injuries to commence during the second half of 2012.”

Later in 2012, the Company plans to submit hydrogel-based applications to the FDA for the treatments of SCI and chronic pain. As the industry of cell-based therapies advances, InVivo also intends to leverage the Company’s acute SCI treatments to expand to chronically injured patients. InVivo has pioneered a new treatment that uses a biocompatible polymer-based scaffolding to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovering and prognosis after a traumatic SCI. Today, there is no effective treatment for the spinal cord for paralysis caused by SCIs, and the market potential for acute SCI is estimated to be over $10 billion.

PRINT PDF

CAMBRIDGE, Mass. (April 11, 2011) – InVivo Therapeutics Holdings Corp. (OTC/BB:
NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that CEO Frank Reynolds is scheduled to appear on local TV affiliates in Charlotte, Indianapolis and Greensboro. The planned schedule includes:

• WBTV-TV, the CBS affiliate in Charlotte, NC, on Saturday, April 14, at 6:50 AM EDT
• WXIN-TV, the FOX affiliate in Indianapolis, IN, on Monday, April 16, at 9:45 AM EDT
• WFMY-TV, the CBS affiliate in Greensboro, NC, on Tuesday, April 17, at 7:45 AM EDT

InVivo Therapeutics has pioneered a new treatment that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after a traumatic spinal cord injury. In addition to the scaffold, Reynolds will discuss the company’s portfolio of technologies for other areas of the nervous system, including innovative injectable hydrogel products the company intends to submit to the U.S. Food and Drug Administration (FDA) in 2012.

“Our technology is a true platform that can be leveraged to create many products, including hydrogel treatments for peripheral nerve injury and other conditions. We’re currently under review at FDA for our first spinal cord injury treatment, and we look forward to receiving approval to begin those human studies,” said Reynolds.

CEO Frank Reynolds discusses InVivo Therapeutics on WBTV-TV, the CBS affiliate in Charlotte, NC.

CEO Frank Reynolds discusses InVivo Therapeutics on WXIN-TV, the FOX affiliate in Indianapolis, IN.

“As a company with a primary focus on developing treatments for SCI, we are proud to continue our support of the Greater Boston Chapter of the National Spinal Cord Injury Association,” said InVivo Chief Science Officer Edward Wirth III, MD, PhD who spoke at Saturday’s gala. “The GBC has made a significant impact on the lives of SCI patients through their Early Intervention Program, Peer Visitation Program, support groups, and advocacy services, and we honored to contribute to these efforts.”

Print PDF

InVivo has pioneered a new treatment that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovering and prognosis after a traumatic spinal cord injury. Today, there is no effective treatment for the spinal cord for paralysis caused by SCIs, and the market potential is estimated to be over $10 billion.

“2011 was a landmark year for InVivo, performing under budget for the sixth consecutive year.  We made significant progress advancing the commercialization of our first product for SCI and expanding our product pipeline to the rest of the nervous system.  We also laid the groundwork to have three product applications under review by FDA by the end of 2012”, said Frank Reynolds, InVivo’s Chief Executive Officer. “Our biopolymer scaffolding is poised to enter human clinical trials for SCI during the second half of 2012 and we expect to file two additional Investigational Device Exemptions for our hydrogel products to treat both SCI and chronic pain from peripheral nerve injuries. We’ve had a great start to 2012 by closing an oversubscribed $20 million public offering led by globally-recognized healthcare investment institutions and by adding key leadership to our senior management team.”

Recent Corporate Highlights

Biopolymer Scaffolding Scheduled to Enter Clinical Studies for SCI in 2012: InVivo expects to commence a pilot human clinical trial during the second half of 2012 pending approval of an Investigational Device Exemption (IDE) application by the FDA. The study will be an open label study and is designed to evaluate the safety and efficacy in ten SCI patients following treatment with the biopolymer scaffolding. This study follows promising pre-clinical studies completed in non-human primates.  InVivo is the first to successfully demonstrate functional improvement in non-human primates that were paralyzed after a spinal cord injury model. Data from this study was published in the Journal of Neuroscience Methods and won the prestigious 2011 Apple Award from the American Spinal Injury Association recognizing excellence in SCI research.

IDE Submissions to be Filed with FDA for Injectable Hydrogel to Treat Peripheral Nerve Injuries and SCI: InVivo has commenced a preclinical study with Geisinger Health System to evaluate the Company’s injectable biocompatible hydrogel for the treatment of chronic pain caused by peripheral nerve compression. Approximately 3.2 million pain injections are performed annually to treat back, neck and leg pain caused by peripheral nerve compression. InVivo’s hydrogel is designed to time-release anti-inflammatory drugs for extended pain relief. The product addresses a $15 billion market for peripheral nerve injuries. InVivo expects to file two IDEs in the second half of 2012 for the use of the injectable hydrogel to treat peripheral nerve injuries and SCI.

Raised $23 Million of Equity Capital: In February 2012, InVivo completed a $20 million public offering led by a select group of institutional investors. The Company issued 9,523,810 shares of common stock at a price to the public of $2.10 per share. Net proceeds to InVivo were approximately $18.1 million. In December 2011, InVivo completed a private placement of common stock and warrants with an existing institutional investor that raised $2 million of net proceeds. In the fourth quarter of 2011, warrants with an exercise price of $1.40 per share were exercised providing $1 million of cash. InVivo has the potential to receive an additional $18.6 million from the exercise of warrants.

Key Additions to the Senior Management Team: InVivo announced the appointments of Edward Wirth III, MD, PhD, formerly of Geron, as its Chief Science Officer, Brian Hess, formerly of Stryker, as Director of Product Development, and Jonathan Slotkin, MD as Medical Director.

Opening New Corporate Headquarters including Manufacturing & Research Facilities: In December 2011, InVivo executed a multi-year lease for a 21,000 square foot facility at One Kendall Square in Cambridge, MA. The new facility will house corporate offices, lab space, a rodent vivarium and a cGMP clean room to meet the needs for the planned human clinical studies.

Financial Results

For the year ended December 31, 2011, the Company reported a net loss of $34,728,000, or $0.67 per diluted share, compared with a net loss of $7,911,000, or $0.24 per diluted share, for the year ended December 31, 2010. Included in net loss for the years ended December 31, 2011 and 2010 were non-cash derivative losses of $26,066,000, and $3,953,000, respectively, reflecting increases in the fair value of the derivative warrant liability. Exclusive of the non-cash derivative loss, the pro forma net loss for the year ended December 31, 2011 was $8,662,000, or $0.17 per diluted share, compared to $3,958,000, or $0.12 per diluted share for 2010. Total operating expenses for the year ended December 31, 2011 were $8,659,000 compared with $3,397,000 for the year ended December 31, 2010. Research and development expense for the year ended December 31, 2011 was $4,103,000, up from $1,673,000 in 2010 as the Company broadened its portfolio of products, added personnel and prepared to initiate a clinical trial. General and administrative expense for the year ended December 31, 2011 rose to $4,556,000 from $1,724,000 in 2010 as the Company made investments to expand infrastructure and incurred costs associated with public company practices.

InVivo Therapeutics Holdings Corp. A Developmental Stage Company Pro Forma Results

InVivo is providing pro forma results as a complement to GAAP results. The pro forma net loss and pro forma diluted loss per share excludes the derivative loss which is a non-cash item. InVivo’s management believes this pro forma measurement helps to indicate underlying trends in the Company’s ongoing operations. The reconciliation between pro forma and reported loss per share for the years ended December 31, 2011 and 2010 is provided in the following table:

Print PDF

CAMBRIDGE, Mass. (March 13, 2011) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries(SCI), today announced that CEO Frank Reynolds is scheduled to appear on KVVU-TV’s Fox 5 News: Live in Las Vegas on Friday, March 16that 8:45am PDT.

InVivo Therapeutics has pioneered a new treatment that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after a traumatic spinal cord injury.  In addition to the scaffold, Reynolds will discuss applications for the technology in other areas of the nervous system, including additional products the company intends to submit to the U.S. Food and Drug Administration (FDA) in 2012.

“Our technology is a true platform that can be leveraged to create many products, includingtreatments for peripheral nerve injury and other conditions. We’re currently under review at FDA for our first spinal cord injury treatment, and we look forward to receiving approval to beginthose human studies,” said Reynolds.

Fox 5 News: Live in Las Vegas airs weekdays from 7:00-9:00am PDT on KVVU-TV, the FOX affiliate on channel 5 for the greater Las Vegas area.

Print PDF

CEO Frank Reynolds Discusses InVivo Therapeutics Latest Advances in Spinal Cord Injury Treatment.

CAMBRIDGE, Mass. (March 7, 2011) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries(SCI), today announced that CEO Frank Reynolds is scheduled to appear on KTVI-TV’s Fox 2 News in the Morning at 7:40am CST on Monday, March 12thin St. Louis, MO.InVivo Therapeutics has pioneered a new treatment platform that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after a traumatic spinal cord injury.  Reynolds will discuss the scaffold and how it is expected to work in humans, as well as results from InVivo’s largest non-human primate study.

“We expect that our technology will change the standard care for spinal cord injury treatment.  We’re currently under review at FDA and we look forward to receiving approval to begin human studies,” said Reynolds. “Our therapeutic approach confirms a clear paradigm shift in the treatment of spinal cord injuries.”

Fox 2 News in the Morning is the morning show for KTVI-TV, the FOX affiliate for the St. Louis market.

Print PDF

CEO Frank Reynolds Discusses InVivo Therapeutics Latest Advances in Spinal Cord Injury Treatment.